Submit Manuscript  

Article Details


Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem

[ Vol. 17 , Issue. 2 ]

Author(s):

Suresh J. Antony and Leigh G. Cooper   Pages 77 - 80 ( 4 )

Abstract:


Prosthetic joint infections (PJI) result in significant morbidity, mortality and cost to patients and the health system. Traditional treatment involves a twostaged revision and occasionally a single staged revision along with intravenous antibiotics (IV) and or oral antibiotics for several weeks to months. The use of a single staged revision along with an antibiotic which has a prolonged half life and is bactericidal would be ideal. We present 2 patients who were treated successfully with a single stage revision/antibiotic spacer and a new novel long acting lipoglycopeptide called oritavancin.

Keywords:

Oritavancin, prosthetic joint, intravenous, lipoglycopeptide, Morbidity, lipoglycopeptide.

Affiliation:

1205 N. Oregon, El Paso, Texas 79902, Department of Medicine, Section of Infectious Diseases, Texas Tech University Health Sciences Center, El Paso, Texas

Graphical Abstract:



Read Full-Text article